To include your compound in the COVID-19 Resource Center, submit it here.

Galapagos reports Phase II CF data for GLPG2222 combo

Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG) said cystic fibrosis candidate GLPG2222 plus Kalydeco ivacaftor significantly reduced sweat chloride levels vs. placebo plus Kalydeco in the Phase II ALBATROSS trial. The trial enrolled 37 CF patients on long-term

Read the full 350 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE